by Duong Binh Tran  , Sinh The Pham  , Binh Xuan Luong  and Thi Cao

Received: 16 November 2025;  Published: 26 May 2026;  doi: 10.21926/obm.transplant.2602271

Aseptic femoral shaft nonunion represents a biologically compromised state in which impaired osteogenesis, insufficient vascularity, and inadequate mechanical stability prevent healing. Although mechanical revision is essential, achieving union often requires effective autologous bone tissue transplantation and biologic stimulation. This study evaluated a multimodal revision strategy integrating structural and cancellous autografts with mechanical reconstruction to restore both biological viabil [...]

by Isrovanigoro  , Lolita  , Adnan  , Metalia Puspitasari  and Zijie Wang

Received: 27 January 2026;  Published: 09 May 2026;  doi: 10.21926/obm.transplant.2602270

Kidney transplantation is the preferred therapy for end-stage kidney disease (ESKD), but long-term success is greatly influenced by the selection and safety of immunosuppressants. Local data on prescribing patterns and the incidence of drug side effects in Indonesia are still limited. Therefore, this study aims to evaluate induction therapy patterns, immunosuppressant maintenance, and the incidence of drug-related side effects among kidney transplant recipients at a tertiary hospital in Yogyakar [...]

by Douglas O. Sobel  and Keerat Parmar

Received: 31 August 2025;  Published: 14 April 2026;  doi: 10.21926/obm.transplant.2602269

Subcutaneous transplantation of islets into small-pore macroencapsulation devices that prevent immune cell passage can inhibit allorejection in rodents. However, there are no reports of euglycemia in humans using this technology. This report further develops these macroencapsulation devices. We compared the ability of macroencapsulation transplant devices containing transformed mouse islet cells (MIN-6) with varying polymer membranes, pore sizes, and hydrophilicity to inhibit allorejection and m [...]